CONSULTING AGREEMENTConsulting Agreement • January 18th, 2019 • Karyopharm Therapeutics Inc. • Pharmaceutical preparations • Massachusetts
Contract Type FiledJanuary 18th, 2019 Company Industry JurisdictionThis Consulting Agreement (the “Agreement”), effective as of January 18, 2019 (the “Effective Date”), is entered into between Karyopharm Therapeutics Inc. (the “Company”) and Michael Falvey (the “Consultant”). The Consultant and Company are referred to in this Agreement individually as a “Party” and collectively as the “Parties”.
VIA HAND DELIVERY January 17, 2019 Michael Falvey Dear Mike:Severance Agreement • January 18th, 2019 • Karyopharm Therapeutics Inc. • Pharmaceutical preparations • Massachusetts
Contract Type FiledJanuary 18th, 2019 Company Industry JurisdictionAs we discussed, your employment with Karyopharm Therapeutics Inc. (the “Company”) will end effective January 18, 2019 (the “Resignation Date”). As we also discussed, you will be eligible to receive the severance benefits described in paragraph 1 below if you (i) sign and return this letter agreement (the “Agreement”) to me by January 18, 2019 (but no earlier than the Resignation Date) and comply with all terms hereof, and (ii) sign and return the Additional Release attached hereto as Attachment A no later than February 7, 2019, and do not revoke your agreement to the Additional Release (attached hereto as Attachment A). By signing and returning this Agreement and the Additional Release (and not revoking the Additional Release), you will be entering into binding agreements with the Company and will be agreeing to the terms and conditions set forth in the numbered paragraphs below, including the releases of claims set forth in paragraph 2 and the Additional Release. Therefore, you are a
January 17, 2019 Cameron Peters Re: Retention Bonus Agreement Dear Cameron,Retention Bonus Agreement • January 18th, 2019 • Karyopharm Therapeutics Inc. • Pharmaceutical preparations
Contract Type FiledJanuary 18th, 2019 Company IndustryWe value your knowledge and contributions at Karyopharm Therapeutics Inc. (as used herein the “Company”). The Company wants you to remain committed and focused on continuing to deliver your goals and objectives. As an incentive for you to remain employed with the Company and help us drive our objectives, the Company is offering you two lump sum retention payments, subject to the terms and conditions of this letter agreement (the “Agreement”) listed below.